RadNet (NASDAQ:RDNT) vs. Tempus AI (NASDAQ:TEM) Head-To-Head Analysis

RadNet (NASDAQ:RDNT) and Tempus AI (NASDAQ:TEM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Profitability

This table compares RadNet and Tempus AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
Tempus AI	-17.77%	-50.28%	-10.33%

Analyst Ratings

This is a breakdown of current ratings for RadNet and Tempus AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1	0	5	3	3.11
Tempus AI	2	9	11	0	2.41

RadNet currently has a consensus price target of $90.00, suggesting a potential upside of 22.47%. Tempus AI has a consensus price target of $72.47, suggesting a potential upside of 0.35%. Given RadNet’s stronger consensus rating and higher probable upside, equities analysts clearly believe RadNet is more favorable than Tempus AI.

Institutional & Insider Ownership

77.9% of RadNet shares are held by institutional investors. Comparatively, 24.2% of Tempus AI shares are held by institutional investors. 5.1% of RadNet shares are held by company insiders. Comparatively, 24.3% of Tempus AI shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

RadNet has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Tempus AI has a beta of 3.54, meaning that its share price is 254% more volatile than the S&P 500.

Earnings & Valuation

This table compares RadNet and Tempus AI”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.27 billion	2.55	-$18.65 million	($0.27)	-272.19
Tempus AI	$1.27 billion	10.25	-$245.03 million	($1.44)	-50.15

RadNet has higher revenue and earnings than Tempus AI. RadNet is trading at a lower price-to-earnings ratio than Tempus AI, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats Tempus AI on 10 of the 15 factors compared between the two stocks.

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.